Fix Your Funds

Investing in stocks often involves navigating fluctuations in share prices, but a rising share price doesn't necessarily mean a company has lost its value. Resmed CDI ( ASX: RMD ) serves as a prime example of this principle, with its share price making a notable recovery since its October 2023 lows. Despite the significant uptick, there's still ample potential for further gains. Image Credit: Pexels Resmed's Impressive Recovery Resmed, a prominent provider of respiratory devices for treating obstructive sleep apnea (OSA), has experienced a remarkable resurgence in its share price. From its lowest point in October 2023 at $21.14, the company's shares have surged by 41% to reach their current level of $29.90. Additionally, Resmed is an ASX healthcare stock . Valuation and Growth Prospects While Resmed shares may no longer be trading at bargain basement prices, with a price-to-earnings (P/E) ratio of 32 times FY2024 earnings, the company remains in line with the global me...

Investors in the Australian stock market have been closely monitoring the performance of CSL Ltd (ASX: CSL) and Resmed CDI ( ASX: RMD ) shares, both of which operate in the healthcare sector. Despite recent fluctuations in their share prices, these companies continue to play significant roles in providing innovative healthcare solutions globally. Image Credit: Pexels CSL Ltd: A Leader in Biotechnology CSL Ltd is a renowned global biotechnology company known for developing and delivering life-saving medicines. With a focus on addressing life-threatening medical conditions, CSL operates through three main business units: CSL Behring, CSL Seqirus, and CSL Vifor. CSL Behring specializes in manufacturing and distributing blood plasma products, while CSL Seqirus focuses on flu-related products and pandemic-related services. CSL Vifor develops products for iron deficiency and nephrology. Business Operations and Acquisitions ASX:CSL relies on plasma and blood collections to support its prima...